/AURA

AURA Stock - Aura Biosciences, Inc.

Q: What is the analyst price target for AURA?

Analyst price target information is not currently available for AURA.

Q: What is AURA's market cap?

Market capitalization information is not currently available for AURA.

Healthcare|Biotechnology|NASDAQ

$5.86+1.38%

+$0.08 (+1.38%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+275.4%upside

Target: $22.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AURA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.44

52W High$8.60

52W Low$4.34

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	$-1,295,000	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-96,116,000	$-84,991,000	$-60,295,000	$-35,250,000	$-22,206,000
Net Income	$-86,919,000	$-76,408,000	$-58,763,000	$-35,251,000	$-22,206,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.75	$-1.93	$-1.96	$-1.58	$-1.03

Company Overview

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

6 Bullish0 Neutral/Bearish

Price Targets

$24

Average Target

↑ 309.6% Upside

Now

$13

Low

$24

Average

$38

High

Based on 5 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 26th 2025	Evercore ISI	Resumed	Outperform	$13
May 28th 2025	H.C. Wainwright	Resumed	Buy	$22
July 25th 2024	H.C. Wainwright	Initiation	Buy	$21
July 27th 2023	Scotiabank	Initiation	Sector Outperform	-
April 17th 2023	BTIG Research	Resumed	Buy	$38
July 19th 2022	JMP Securities	Initiation	Mkt Outperform	$26

Earnings History & Surprises

AURA

Beat Rate

63%

Last 16 quarters

Avg Surprise

-32.5%

EPS vs Estimate

Beats / Misses

10/5

1 met exactly

Latest EPS

$-0.40

Q4 2025

EPS Surprise History

Q1 24

-28.2%

$-0.50vs$-0.39

Q2 24

+21.6%

$-0.40vs$-0.51

Q3 24

+8.9%

$-0.41vs$-0.45

Q4 24

+4.5%

$-0.42vs$-0.44

Q1 25

-20.9%

$-0.52vs$-0.43

Q2 25

-17.0%

$-0.55vs$-0.47

Q3 25

+4.1%

$-0.47vs$-0.49

Q4 25

+13.0%

$-0.40vs$-0.46

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 23, 2026	$-0.43	—	—	—
Q4 2025	Nov 13, 2025	$-0.46	$-0.40	+13.0%	✓ BEAT
Q3 2025	Aug 13, 2025	$-0.49	$-0.47	+4.1%	✓ BEAT
Q2 2025	May 15, 2025	$-0.47	$-0.55	-17.0%	✗ MISS
Q1 2025	Mar 24, 2025	$-0.43	$-0.52	-20.9%	✗ MISS
Q4 2024	Nov 12, 2024	$-0.44	$-0.42	+4.5%	✓ BEAT
Q3 2024	Aug 8, 2024	$-0.45	$-0.41	+8.9%	✓ BEAT
Q2 2024	May 9, 2024	$-0.51	$-0.40	+21.6%	✓ BEAT
Q1 2024	Mar 27, 2024	$-0.39	$-0.50	-28.2%	✗ MISS
Q4 2023	Nov 9, 2023	$-0.54	$-0.48	+11.1%	✓ BEAT
Q3 2023	Aug 9, 2023	$-0.49	$-0.48	+2.0%	✓ BEAT
Q2 2023	May 11, 2023	$-0.52	$-0.46	+11.5%	✓ BEAT
Q1 2023	Mar 15, 2023	$-0.58	$-0.52	+10.3%	✓ BEAT
Q4 2022	Nov 10, 2022	$-0.52	$-0.53	-1.9%	✗ MISS
Q3 2022	Aug 11, 2022	$-0.48	$-0.46	+4.2%	✓ BEAT
Q2 2022	May 12, 2022	$-0.44	$-0.44	0.0%	= MET
Q1 2022	Mar 23, 2022	$-0.39	$-2.51	-543.6%	✗ MISS
Q4 2021	Nov 24, 2021	—	$-0.32	—	—
Q4 2021	Nov 1, 2021	—	$-0.45	—	—
Q1 2021	Mar 31, 2021	—	$-0.30	—	—

Frequently Asked Questions about AURA

What is AURA's current stock price?

Aura Biosciences, Inc. (AURA) is currently trading at $5.86 per share. The stock has moved +1.38% today.

What is the analyst price target for AURA?

The average analyst price target for AURA is $22.00, based on 1 analyst.

What sector is Aura Biosciences, Inc. in?

Aura Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is AURA's market cap?

Aura Biosciences, Inc. has a market capitalization of $0.37 billion, making it a small-cap company.

Does AURA pay dividends?

No, Aura Biosciences, Inc. does not currently pay a dividend to shareholders.